| Field | Specification |
|---|---|
| Target | |
| Alternative names | BRCA1; RNF53; Breast cancer type 1 susceptibility protein; RING finger protein 53 |
| Gene ID | |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human BRCA1. AA range:1491-1540 |
| Conjugate | |
| Purification | |
| Concentration | |
| Formulation | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
BRCA1encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein (BRCA1, DNA repair associated) combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.
Product Overview
This polyclonal antibody, raised in Rabbit, recognizes BRCA1. It is validated for Western Blot, Immunohistochemistry, ELISA.
Validated Applications
| Applications | Western Blot, Immunohistochemistry, ELISA |
|---|
Optimal dilutions should be determined by the end user for each application and sample type.
Immunogen
The antiserum was produced against synthesized peptide derived from human BRCA1. AA range:1491-1540
Specifications
| Host | Rabbit |
|---|---|
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human |
| Immunogen | The antiserum was produced against synthesized peptide derived from human BRCA1. AA range:1491-1540 |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration | 1 mg/ml |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Target MW | 207721 Da |
| UniProt Accession | Human: P38398; Mouse: P48754 |
| Gene ID | Human: 672 |
| Storage | -20°C for 1 year |
| Lead Time | Within one week |
Reactivity Notes
Validated reactivity: Human. For other species, epitope conservation may allow cross-reactivity; confirm with appropriate controls.
Safety & Handling
This product is for research use only (RUO) and is not intended for diagnostic or therapeutic use. The formulation contains sodium azide; handle with standard laboratory precautions.
Related Products
Explore related antibodies and reagents for BRCA1 research from Bioassay Technology Laboratory, or contact us for alternative formats.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
